34 results about "Brucella abortus" patented technology

Compositions and methods for the diagnosis and prevention of B. abortus infection are provided.

Compositions and methods for the diagnosis and prevention of B. abortus infection are provided.

Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms. Functional inactivation of galE, a virB gene or the operon (ORFs 1087-1090) comprising the gene encoding β-hexosaminidase (BMEI1087) and a lytic murein transglycosylase gene (BMEI1088). A specific example of the attenuated galE mutant which produces a protective immune response is B. melitensis GR024. The specific example of an inactivated ORF1087-1090 operon is B. melitensis GR026; it has an insertion mutation in the promoter region upstream of ORF 1090. Vaccination with live cells of either or both of these mutants results in a T cell response which protects the human or animal against challenge with virulent B. melitensis. Similar strategies for protective immunity using live attenuated mutants are useful for B. abortus, B. suis and B. ovis as well.

Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.

This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted “survivor” antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD50s of F. tularensis LVS.

A PCR kit for simultaneously detecting Brucella abortus, Brucella melitensis, Brucella suis and Brucella canis as well as a preparation method and a using method thereof, and belongs to the field of gene detection of anthropozoonosis pathogens. The PCR kit comprises a PCR liquid reactant, DNA polymerase, positive quality control standard substances and negative quality control standard substances; the PCR liquid reactant comprises four pairs of primers for identifying Brucella abortus, Brucella melitensis, Brucella suis and Brucella canis and a PCR buffer solution containing dNTPs, Mg<2+> and double distilled water. The PCR kit has high practicability, can be used for directly detecting the type of Brucella in a contaminated sample, has high detection speed, high sensitivity (10<2>cfu / ml), high specificity and good repeatability, is safe, reliable, quick, simple and convenient, can be used for qualitative detection of the type of Brucella in the sample, and can replace traditional etiological and serological methods.

Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms. Functional inactivation of galE, a virB gene or the operon (ORFs 1087-1090) comprising the gene encoding β-hexosaminidase (BMEI1087) and a lytic murein transglycosylase gene (BMEI1088). A specific example of the attenuated galE mutant which produces a protective immune response is B. melitensis GR024. The specific example of an inactivated ORF1087-1090 operon is B. melitensis GR026; it has an insertion mutation in the promoter region upstream of ORF 1090. Vaccination with live cells of either or both of these mutants results in a T cell response which protects the human or animal against challenge with virulent B. melitensis. Similar strategies for protective immunity using live attenuated mutants are useful for B. abortus, B. suis and B. ovis as well.

Based on the genes of Brucella abortus, Mycobacterium bovis and Chlamydia abortus, the present invention designs three pairs of specific amplification primers for the three pathogens, cooperates with the PCR reaction components, and establishes a multiplex PCR method for detecting and distinguishing the three kinds of cattle Single or mixed infection of common pathogens, and packaging of detection kits for the detection and differentiation of Brucella bovis, Mycobacterium bovis and Chlamydia bovis.